The Japan Neuromyelitis Optica Spectrum Disorders/Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease Registry

ABSTRACT In Japan, five biologics (eculizumab, ravulizumab, satralizumab, inebilizumab, and rituximab) are currently available for treating neuromyelitis optica spectrum disorder (NMOSD). These biologics have dramatically suppressed the disease relapse rate; however, a big problem remains: there are no useful biomarkers or sufficient evidence in drug selection and drug switch for each patient. Myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) has been recently identified, and its therapeutic strategy is still under investigation. To solve these problems, the Japan NMOSD/MOGAD Registry was launched in December 2023. In this paper, we summarize the current clinical problems of NMOSD and MOGAD in Japan and review the Japan NMOSD/MOGAD Registry project.

Authors

Institutions

Publication Details

Journal
Clinical and Experimental Neuroimmunology
Published
2025-08-30
DOI
https://doi.org/10.1111/cen3.70023
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Japan Neuromyelitis Optica Spectrum Disorders/Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease Registry

Yusei Miyazaki, Katsuhisa Masaki, Takao Kiriyama, Kengo Nagashima et al.
Clinical and Experimental Neuroimmunology
Multiple Sclerosis Research Studies
article

The Japan Neuromyelitis Optica Spectrum Disorders/Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease Registry

Yusei Miyazaki, Katsuhisa Masaki, Takao Kiriyama, Kengo Nagashima, Hideyuki Takeuchi, Nobuaki Yoshikura, Ichiro Nakashima, Katsuichi Miyamoto, Juichi Fujimori, Shoko Ukita, Sonoko Misawa, Hikoaki Fukaura
article en

Abstract

ABSTRACT In Japan, five biologics (eculizumab, ravulizumab, satralizumab, inebilizumab, and rituximab) are currently available for treating neuromyelitis optica spectrum disorder (NMOSD). These biologics have dramatically suppressed the disease relapse rate; however, a big problem remains: there are no useful biomarkers or sufficient evidence in drug selection and drug switch for each patient. Myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) has been recently identified, and its therapeutic strategy is still under investigation. To solve these problems, the Japan NMOSD/MOGAD Registry was launched in December 2023. In this paper, we summarize the current clinical problems of NMOSD and MOGAD in Japan and review the Japan NMOSD/MOGAD Registry project.

Clinical and Experimental NeuroimmunologyVol. 17(1)
Kyushu University (JP), Chiba University (JP), Wakayama Medical University (JP), National Hospital Organization Hokkaido Medical Center (JP), Keio University Hospital (JP), International University Of Health And Welfare Atami Hospital (JP), Gifu University (JP), Nara Medical University (JP), International University of Health and Welfare (JP), Tohoku Medical and Pharmaceutical University (JP), Saitama Medical University (JP), Yokohama City University (JP)
Ministry of Health, Labour and Welfare
Openalex Percentile: Top 67%
Multiple Sclerosis Research Studies
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.